Somatostatin Agonists
    14.
    发明申请
    Somatostatin Agonists 审中-公开
    生长抑素激动剂

    公开(公告)号:US20090258853A1

    公开(公告)日:2009-10-15

    申请号:US12225027

    申请日:2007-03-09

    摘要: This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof.

    摘要翻译: 本发明涉及作为生长抑素的激动剂并且对生长抑素受体亚型SSTR2有选择性的化合物。 该化合物可用于治疗和预防糖尿病以及糖尿病相关病理学,包括视网膜病变,神经病变和肾病。 许多化合物是口服活性的。 因此,本发明的目的是描述这些化合物。 进一步的目的是描述生长抑素激动剂的具体优选的立体异构体。 另一个目的是描述制备这些化合物的方法。 另一个目的是描述使用这些化合物作为其活性成分的方法和组合物。

    Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
    17.
    发明申请
    Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 审中-公开
    代谢型谷氨酸受体-5的二芳基取代的吡唑调节剂

    公开(公告)号:US20060194807A1

    公开(公告)日:2006-08-31

    申请号:US10551709

    申请日:2004-03-30

    摘要: Novel pyrazole compounds such as compounds of the formula (I): (where A, A1, A2, B, R11, W, X, Y and Z are as defined herein) in which the pyrazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, obesity, drug addiction, drug abuse, drug withdrawal and other diseases.

    摘要翻译: 新的吡唑化合物,例如式(I)的化合物:其中A,A 1,A 2,B,R 11,W ,X,Y和Z如本文所定义),其中吡唑直接被取代,或通过桥取代,其中i)杂芳基部分含有与杂芳基的连接点相邻的N,和ii)另一个杂芳基或芳基环 ,其中至少一个环被另一个环取代,是用于治疗精神病和情绪障碍的mGluR5调节剂,例如精神分裂症,焦虑症,抑郁症,恐慌症和双相情感障碍,以及在 治疗疼痛,帕金森病,认知功能障碍,癫痫,昼夜节律紊乱,肥胖,药物成瘾,药物滥用,戒毒等疾病。